Tablets & Capsules


Issue link:

Contents of this Issue


Page 7 of 51

6 May/June 2021 Tablets & Capsules markets Rising demand for generics to boost pharmaceutical contract development and manufacturing market NORTHBROOK, IL—The global pharmaceutical contract development and manufacturing market is projected to grow at a compound annual rate of 7.7 percent through 2025, reaching $146.1 billion, according to a report by MarketsandMarkets. Factors driv- ing market growth include the rising demand for generics, increasing invest- ments in pharmaceutical R&D, and CDMO investments in advanced man- ufacturing technologies. The European region accounted for the largest mar- ket share, which can be attributed to the number of clinical trials in the region, a large API production base, advanced manufacturing capabilities, and the presence of leading pharma- ceutical companies in Europe. The report identified Thermo Fisher Sci- entific, Catalent, Lonza, Recipharm, AbbVie, Aenova, Almac, Siegfried Holding, and Ingelheim International as key market players. Global API market to grow 5.8 percent annually through 2025 NORTHBROOK, IL—The global active pharmaceutical ingredient (API) market is forecast to reach $248.3 bil- lion by 2025, growing at a compound annual rate of 5.8 percent, according to a report by MarketsandMarkets. Sev- eral factors are driving market growth, including the increasing occurrence of chronic diseases, growing demand for generics, and the increasing uptake of biopharmaceuticals. North America held the largest market share, largely due to the prevalence of chronic dis- eases, governmental focus on generics, the rising demand for biologics and spe- cialty drugs, and advancements in API manufacturing technology. Key mar- ket players named in the report include Pfizer, Novartis, Merck, Teva Pharma- ceutical, Mylan, Boehringer Ingelheim, F. Hoffman-La Roche, Sanofi, AbbVie, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, and GlaxoSmithKline. industry news FDA approves first novel ADHD treatment for pediatrics SILVER SPRING, MD—The FDA approved Qelbree (viloxazine) for the treatment of attention-deficit hyper- activity disorder (ADHD) in pediatric patients ages 6 to 17. The drug, manu- factured by Supernus Pharmaceuticals, is the first novel non-stimulant treatment for ADHD approved by the agency in a decade. FDA publishes guidance on ANDA development during the pandemic SILVER SPRING, MD—The FDA published a new guidance for indus- try, "Development of Abbreviated New Drug Applications During the Covid-19 Pandemic – Questions and Answers," which provides general rec- ommendations in the form of questions and answers on generic drug product development, ANDA submission and assessment, and marketing and exclusiv- ity, among other topics. The questions were submitted to the agency by ANDA applicants and prospective applicants and about generic drug product devel- opment and application assessment during the ongoing Covid-19 pandemic. IPEC publishes position paper on low risk of lactose in oral preparations ARLINGTON, VA—The Inter- national Pharmaceutical Excipients Council Federation, (IPEC Federa- tion), a trade organization representing excipient producers, distributors, and finished drug manufacturers, has pub- lished a position paper, "Pharmaceutical lactose used in oral preparations is a low-risk excipient." This paper explains the organization's position on the risk classification of lactose in all oral prepa- rations. Globally, many regulatory bodies are seeking to classify pharma- ceutical excipients according to the risk they may present to patients when used in dosage forms. The federation con- siders that pharmaceutical-grade lactose has a low risk profile with respect to chemical and biological risks when used • Lean, dense phase, plug-flow conveying of powders & small particles • Gentle - segregation & damage free • Conveying rates up to 10,000 lbs/hr • Safe, explosion free • Quiet, hygienic, reliable • No tools assembly Simply the best vacuum conveyor 609-265-0101 PUT US TO THE TEST Courtesy of Weiss Pharmatechnik GmbH

Articles in this issue

Links on this page

Archives of this issue

view archives of Tablets & Capsules - TCMay/June21